AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012

The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.